Reneo Pharmaceuticals Stock (NASDAQ:RPHM)
Previous Close
$1.73
52W Range
$1.68 - $82.90
50D Avg
$14.92
200D Avg
$16.09
Market Cap
$60.84M
Avg Vol (3M)
$17.98K
Beta
0.22
Div Yield
-
RPHM Company Profile
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
RPHM Performance
Peer Comparison
Ticker | Company |
---|---|
DNA | Ginkgo Bioworks Holdings, Inc. |
CNSP | CNS Pharmaceuticals, Inc. |
ADPT | Adaptive Biotechnologies Corporation |
CGEM | Cullinan Oncology, Inc. |
DBTX | Decibel Therapeutics, Inc. |
APLS | Apellis Pharmaceuticals, Inc. |
EWTX | Edgewise Therapeutics, Inc. |
PRME | Prime Medicine, Inc. |
LEGN | Legend Biotech Corporation |
AVRO | AVROBIO, Inc. |
VIR | Vir Biotechnology, Inc. |
KRON | Kronos Bio, Inc. |
CCCC | C4 Therapeutics, Inc. |
IMMX | Immix Biopharma, Inc. |
SMMT | Summit Therapeutics Inc. |
RPRX | Royalty Pharma plc |
HOWL | Werewolf Therapeutics, Inc. |
NKTX | Nkarta, Inc. |
OCEA | Ocean Biomedical, Inc. |
HEPA | Hepion Pharmaceuticals, Inc. |
KZR | Kezar Life Sciences, Inc. |
CELC | Celcuity Inc. |